2022
Improving Cancer Care for Patients With CKD: The Need for Changes in Clinical Trials
Sprangers B, Perazella MA, Lichtman SM, Rosner MH, Jhaveri KD. Improving Cancer Care for Patients With CKD: The Need for Changes in Clinical Trials. Kidney International Reports 2022, 7: 1939-1950. PMID: 36090489, PMCID: PMC9458993, DOI: 10.1016/j.ekir.2022.06.005.Peer-Reviewed Original ResearchChronic kidney diseaseEnd-stage kidney diseaseSevere kidney dysfunctionKidney diseaseKidney dysfunctionAdvanced kidney diseaseOptimal clinical careCancer drug trialsNumber of patientsNarrow therapeutic indexInitial clinical studiesKidney replacement treatmentPreregistration studiesKidney functionCancer careReplacement treatmentCancer trialsClinical trialsEffective dosingClinical studiesTreatment decisionsDrug trialsBeneficial drugsClinical carePatients
2021
Immunotherapy-Related Acute Kidney Injury
Manohar S, Jhaveri KD, Perazella MA. Immunotherapy-Related Acute Kidney Injury. Advances In Kidney Disease And Health 2021, 28: 429-437.e1. PMID: 35190109, DOI: 10.1053/j.ackd.2021.07.006.Peer-Reviewed Original ResearchConceptsChimeric antigen receptor T-cell therapyEffective immune checkpoint inhibitorsAcute kidney injuryImmune checkpoint inhibitorsHigh-dose interleukinNumerous clinical trialsT-cell therapyField of oncologyCheckpoint inhibitorsKidney injuryGeneration immunotherapiesClinical trialsClinical practiceImmunotherapyImmune systemAdverse effectsNephrotoxicityInterleukinPathophysiologyInjuryTherapyCancerOncologyTrialsPARP inhibitors and the Kidney
Deshpande P, Perazella M, Jhaveri K. PARP inhibitors and the Kidney. Journal Of Onco-Nephrology 2021, 5: 42-47. DOI: 10.1177/2399369320987090.Peer-Reviewed Original ResearchAcute kidney injuryChronic kidney diseaseIschemic acute kidney injuryEnd-stage kidney diseaseKidney diseaseSepsis-related acute kidney injuryAdvanced chronic kidney diseasePARP inhibitorsPoly (ADP-ribose) polymeraseIncrease serum creatinineUse of PARPisBreast cancer gene mutationsStage kidney diseaseAnti-cancer effectsCancer gene mutationsSafe dosingKidney injurySerum creatinineKidney functionKidney effectsClinical trialsLong-term effectsAnimal modelsCellular necrosisPARPis
2020
Urine interleukin-9 and tumor necrosis factor-α for prognosis of human acute interstitial nephritis
Moledina DG, Wilson FP, Kukova L, Obeid W, Luciano R, Kuperman M, Moeckel GW, Kashgarian M, Perazella MA, Cantley LG, Parikh CR. Urine interleukin-9 and tumor necrosis factor-α for prognosis of human acute interstitial nephritis. Nephrology Dialysis Transplantation 2020, 36: 1851-1858. PMID: 33125471, PMCID: PMC8476079, DOI: 10.1093/ndt/gfaa169.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisTumor necrosis factorCorticosteroid useIL-9Interstitial nephritisNecrosis factorAcute kidney injuryIL-9 levelsGlomerular filtration rateSubset of patientsCohort of participantsImmunosuppressive therapyTubulointerstitial infiltratesKidney injuryMedian eGFRKidney functionUrine biomarkersInterstitial fibrosisFiltration rateHistological featuresClinical trialsInterleukin-9PatientsEGFRComplete dataHow to determine kidney function in cancer patients?
Sprangers B, Abudayyeh A, Latcha S, Perazella MA, Jhaveri KD. How to determine kidney function in cancer patients? European Journal Of Cancer 2020, 132: 141-149. PMID: 32361629, DOI: 10.1016/j.ejca.2020.03.026.Peer-Reviewed Original ResearchConceptsGlomerular filtration rateKidney functionCancer patientsDifferent glomerular filtration ratesAppropriate dose adjustmentCKD-EPI formulaSerum creatinine concentrationNarrow therapeutic indexDose adjustmentFiltration rateClinical trialsCreatinine concentrationTherapeutic indexAnti-cancer drugsPatientsToxic drugsDrugsBody surfaceTrials
2017
Crizotinib: Renal Safety Evaluation
Perazella M, Izzedine H. Crizotinib: Renal Safety Evaluation. Journal Of Onco-Nephrology 2017, 1: 49-56. DOI: 10.5301/jo-n.5000012.Peer-Reviewed Original ResearchNon-small cell lung cancerAdvanced ALK-positive non-small cell lung cancerALK-positive non-small cell lung cancerPositive non-small cell lung cancerAnaplastic lymphoma kinase-1Renal adverse effectsAcute kidney injuryAdverse renal effectsInsulin receptor tyrosine kinase familyCell lung cancerMechanism of actionKidney injuryPeripheral edemaRenal effectsElectrolyte disordersLung cancerClinical indicationsClinical trialsRenal cystsALK inhibitorsReceptor tyrosine kinase familySmall molecule inhibitorsCrizotinibClinical useAdverse effects
2004
Use of Low Molecular Weight Heparins and Glycoprotein IIb/IIIa Inhibitors in Patients with Chronic Kidney Disease
Perazella M, Mosenkis A, Berns J. Use of Low Molecular Weight Heparins and Glycoprotein IIb/IIIa Inhibitors in Patients with Chronic Kidney Disease. Seminars In Dialysis 2004, 17: 411-416. PMID: 15461751, DOI: 10.1111/j.0894-0959.2004.17351.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngina, UnstableDiabetes Mellitus, Type 2Diabetic NephropathiesDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationFollow-Up StudiesHeparin, Low-Molecular-WeightHumansKidney Failure, ChronicMalePlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexRisk AssessmentTreatment OutcomeConceptsLow molecular weight heparinIIb/IIIa inhibitorsChronic kidney diseaseAcute coronary syndromeEnd-stage renal diseaseMolecular weight heparinWeight heparinKidney diseaseGlycoprotein IIb/IIIa inhibitorsGP IIb/IIIa inhibitorsSafety of LMWHLarge prospective trialsMajor clinical trialsCardiac causesCoronary syndromeAppropriate dosingProspective trialRenal diseaseKidney functionAggressive interventionClinical benefitClinical trialsPatientsSignificant impairmentDisease
2001
COX-2 Inhibitors and the Kidney
Perazella M. COX-2 Inhibitors and the Kidney. Hospital Practice 2001, 36: 43-56. PMID: 11263799, DOI: 10.3810/hp.2001.03.230.Peer-Reviewed Original Research